 | Up a level |
Journal Article
Doerner, T., Schulze-Koops, H., Burmester, G. -R., Iking-Konert, C., Schmalzing, M., Engel, A., Kaestner, P., Kellner, H., Kurthen, R., Krueger, K., Rubbert-Roth, A., Schwenke, H., Peters, M. A. and Tony, H. -P. (2019). Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin. Exp. Rheumatol., 37 (6). S. 937 - 946. PISA: CLINICAL & EXPER RHEUMATOLOGY. ISSN 1593-098X
Rubbert-Roth, A., Burmester, G. R., Doerner, T. and Gause, A. (2014). Recommendations for use of rituximab in patients with rheumatoid arthritis. Z. Rheumatol., 73 (2). S. 165 - 174. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1435-1250
Witt, M., Grunke, M., Proft, F., Baeuerle, M., Aringer, M., Burmester, G., Chehab, G., Fiehn, C., Fischer-Betz, R., Fleck, M., Freivogel, K., Haubitz, M., Koetter, I., Lovric, S., Metzler, C., Rubberth-Roth, A., Schwarting, A., Specker, C., Tony, H-P, Unger, L., Wassenberg, S., Doerner, T. and Schulze-Koops, H. (2013). Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus, 22 (11). S. 1142 - 1150. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0962